Journals / Trakya Üniversitesi Tıp Fakültesi Dergisi / 2010 / Cilt: 27 - Sayı: 4

Autologous serum for expansion of human bone marrow derivated mesenchymal stem cell

İnsan kemik iliği kaynaklı mezenkimal kök hücrelerin otolog serum ile kültüre edilmesi

Pages
338–343
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The expansion potency from bone marrow-derived MSCs was maintained in culture media using 10% and 5% OS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Mesenchymal stem cells (MSC), mostly derivated from bone marrow, are capable of differentiating into many tissues.
📊
Key Findings & Data:In the culture medium consisting of 10% fetal bovine serum (FBS), MSCs can grown easily.
💡
Conclusion & Impact:Conclusion: The expansion potency from bone marrow-derived MSCs was maintained in culture media using 10% and 5% OS.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Mesenchymal stem cells (MSC), mostly derivated from bone marrow, are capable of differentiating into many tissues. In the culture medium consisting of 10% fetal bovine serum (FBS), MSCs can grown easily. To obtain insights into their ex-vivo expansion, the role of the autologous serum (OS) on growth and differentiation capacity of human bone marrow MSCs in comparison to cells grown in FBS was studied. Material and Methods: MSCs were cultured by using a RPMI-1640 medium consisting of 10% FBS, and OS 10%, 5%, 3% and 1%. Equally, 1x106/mL cells were incubated into each flask. Cell count, viability, and flow cytometry studies were done at every passage after completing detachment in the cultures. Results: 10% OS group was found to be superior compared to the other study groups as regard to cell count and isolation. In addition, it has been observed that similar resuts were found in 5% OS and 10% FBS groups. Immunophenotyping analysis of the cells revealed no statistical difference between the groups. MSCs isolated from all study groups were successfully differentiated into adipogenic lineages except 3% and 1% OS groups. Conclusion: The expansion potency from bone marrow-derived MSCs was maintained in culture media using 10% and 5% OS.

Özet

Amaç: Mezenkimal kök hücreler (MKH) en sık kemik iliğinden elde edilen ve bir çok dokuya farklılaşma yeteneğine sahip çok yönelimli öncü hücrelerdir. MKH'ler %10 fetal bovin serumlu (FBS) besiyerinde üretilirler. Bu çalışmada amaç FBS'un olası risklerinden uzaklaşılması için otolog serum kullanarak klinik kullanım için uygun MKH üretimini sağlamaktır. Gereç ve Yöntemler: Yaşları 28-34 arasında değişen 10 kemik iliği donoründen yazılı onamları alınarak 10 mL kemik iliği ve 500 mL periferik kan örneği alındı. Kemik iliğinden fikol yoğunluk derecelendirme yöntemiyle mononükleer hücreler izole edildi. Eşit sayıda hücre (1x106/mL) RPMI-1640 medium kullanılarak %10 FBS, otolog serum (OS), %10, %5, %3 ve %1 konsantrasyonlarında kültüre edildi. Her pasaj arasında morfolojik değerlendirme, hücre sayımı ve akım sitometrik yöntemler kullanılarak immunfenotipik analizler yapıldı. Üçüncü pasaja ulaşan gruplarda yağ dokusuna farklılaştırma gerçekleştirildi. Bulgular: Hücre sayımı ve izolasyon açısından en iyi grubun %10 OS grubu olduğu gösterildi. Buna ilave olarak %5 OS ve %10 FBS gruplarındaki sonuçların benzer olduğu gözlemlendi. Akım sitometrik sonuçlar değerlendirildiğinde gruplar arasında istatistiksel fark yoktu. Yağ dokusuna farklılaştırma açısından %3 OS ve %1 OS dışında diğer gruplarda farklılaşma sağlandı. Sonuç: Sonuç olarak özellikle %10 OS ve %5 OS kullanılarak MKH kültürleri yapılabileceği saptandı.

🔖

Cite This Article

KOZANOĞLU, İ., BOĞA, C., MAYTALMAN, E., SÖZER, O., ÖZDOĞU, H. (2010). Autologous serum for expansion of human bone marrow derivated mesenchymal stem cell. Trakya Üniversitesi Tıp Fakültesi Dergisi, Cilt: 27 - Sayı: 4, 338–343. https://ajindex.com/articles/369595

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991;9:641-50
  2. Verfaillie CM, Pera MF, Lansdorp PM. Stem cells: Hype and reality. Hematology 2002:369-91
  3. Dazzi F, Horwood NJ. Potential of mesenchymal stem cell therapy. Curr Opin Oncol. 2007;19:650-5
  4. Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV. Petrakova, Osteogenesis in transplants of bone marrow cells, J Embryol Exp Morphol 1996;16:381-90
  5. Friedenstein AJ. Precursor cells of mechanocytes, Int Rev Cytol 1976; 47: 327-59
  6. Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. The role of mesenchymal stem cells in haemopoiesis. Blood Rev. 2006;20:161-71
  7. Valtieri M, Sorrentino A. The mesenchymal stromal cell contribution to homeostasis. J Cell Physiol. 2008;217:296-300
  8. Arthur A, Zannettino A, Gronthos S. The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. J Cell Physiol. 2008:15;218:237-45
  9. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use, Bone Marrow Transplant 1995;16:557-64
  10. Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000;28:875-84
  11. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, et al., Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone, Proc Natl Acad Sci U S A 99 2002;99:8932-7
  12. K. Le Blanc, C. Tammik, K. Rosendahl, E. Zetterberg and O. Ringden, HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells, Exp Hematol 2003;31:890-6
  13. Psaltis PJ, Zannettino AC, Worthley SG, Gronthos S. Concise review: mesenchymal stromal cells: potential for cardiovascular repair.Stem Cells. 2008;26:2201-10
  14. Verfaillie CM, Schwartz R, Reyes M, Jiang Y. Unexpected potential of adult stem cells. Ann N Y Acad Sci. 2003;996:231-4
  15. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-7
  16. L. Tuschong SL, Soenen RM, Blaese F, Candotti and LM. Muul, Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy, Hum Gene Ther 2002;13:1605-10
  17. Mackensen A, Dräger R, Schles